[DAS] AlphaRX Announces Commercialization of LipoBloc* and LipoLette*
Biotaq.com Support
support@biotaq.com
Wed, 3 Jul 2002 03:26:50 -0400 (EDT)
------=_Part_385011_-1966590049.1025681402550
Content-Type: text/plain; charset=iso-8859-1
Content-Transfer-Encoding: 7bit
BIOTAQ(TM) Newswire (July 3 2002)
AlphaRX Announces Commercialization of LipoBloc* and LipoLette*, Two Unique Proprietary Dietary
Supplements for the Management of High Blood Cholesterol & Weight Control
Richmond Hill, Ontario - July 03, 2002 - AlphaRx Inc. (ALRX:OTCBB) is pleased to announce that production has commenced of LipoBloc* and LipoLette* -
two of its proprietary dietary formulations addressing the multi-billion dollar markets for the management of high blood cholesterol levels and the promotion of
sustainable long-term bodily weight-control. The Company has begun manufacturing in preparation for their product launch, anticipated for September 2002.
Cardiovascular disease is the number one killer in the Western World, with an estimated $200 billion spent on the disease annually. AlphaRx's highly soluble
LipoBloc* has been proven effective in the management of high blood cholesterol levels, as there is a direct correlation between the solubility of phytosterols and
their effectiveness in cholesterol reduction. AlphaRx's LipoBloc* offers consumers a viable dietary supplement that works to reduce cholesterol levels.
AlphaRx's clinically proven delivery system makes LipoBloc* significantly more soluble and bioavailable than other phytosterol products, enhancing their attachment
to cholesterol absorption sites in the small intestine and further reducing serum total and LDL levels as a result. Phytosterols are naturally occurring plant extracts,
which have a molecular structure virtually identical to that of cholesterol but are insoluble in water and oil, thus making them extremely low in bioavailability.
In one clinical trial, 300 mg phytosterols administered in lecithin micelles (such as those used in LipoBloc* reduced cholesterol absorption as much as 34.4% as
compared to a 11.5% reduction in three times the quantity of phytosterols in powder form alone. Thus, there is clearly a direct correlation between the solubility of
phytosterols and their effectiveness in cholesterol absorption.
It is estimated that consumers spend approximately $33 billion annually trying to lose weight or prevent weight gain. AlphaRx's LipoLette* supports effective weight
control "lipotrophically" by decreasing the accumulation of fat in the body. LipoLette's* active ingredients include a natural plant extract that though to inhibit the
action of "lipases," intestinal tract digestive enzymes that are responsible for the body's absorption of fat. This inhibition achieves weight control through reduced fat
intake, eliminating the unabsorbed food through the stool. This mechanism is similar to the popular obesity drug "Xenical," a synthetic prescription "lipase" inhibitor.
As LipoLette* is also free of Ephedra (Ma Huang) and caffeine, LipoLette* addresses the problem of weight control without such adverse side effects as insomnia
and agitation.
About AlphaRx
AlphaRx is engaged in the development of novel formulations of drugs that are insoluble or poorly soluble in water. AlphaRx's broad product pipeline consists of
carefully selected, currently marketed drugs, which, through the application of its proprietary drug delivery technology, offer improved medical benefits over existing
products with a strong commercial potential.
FORWARD LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and
involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and
acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
Note: The FDA has not evaluated these statements. This statement is not intended to diagnose, treat, cure of prevent disease.
Contact:
AlphaRx http://www.alpharx.com Michael M. Lee Tel: 905-762-0745 Ext. 101
Econ Investor Relations
Connie Linder
Toll free: 888-368-8705
Email: clinder@investorideas.com
Biotaq.com Support : You are invited to join Biotaq.com at http://www.biotaq.com/joinbiotaq.htm
Please contact us for distributing your news to this mailing list!
------------------------------------------------
email: support@biotaq.com
voice: Michael M. Lee at 905-762-0745 Ext. 101
web: http://www.biotaq.com
------------------------------------------------
This email has been sent to by Biotaq.com.
Visit our Subscription Center to edit your interests or unsubscribe.
http://ccprod.roving.com/roving/d.jsp?p=oo&m=992813485921&ea=das@biodas.org
View our privacy policy: http://ccprod.roving.com/roving/CCPrivacyPolicy.jsp
------=_Part_385011_-1966590049.1025681402550
Content-Type: text/html; charset=iso-8859-1
Content-Transfer-Encoding: quoted-printable
<HTML>
<!--=20
HTML-FORMATTED MESSAGE BELOW
The remainder of this message is in HTML format for use by email
clients that can properly display it. If you are seeing this message,
it is because your email client cannot properly display HTML. You can
ignore the HTML code you will see below.
-->
<head>
=09<title>AlphaRX Announces Commercialization of LipoBloc* and LipoLette*</=
title>
</head>
<body bgcolor=3D"#ffffff" leftmargin=3D"0" topmargin=3D"0" marginwidth=3D"0=
" marginheight=3D"0">
<IMG SRC=3D"http://rs6.net/on.jsp?t=3D1010994793318.1010994671712&o=3Dhttp:=
//ccprod.roving.com/roving/images/p1x1.gif" WIDTH=3D1 HEIGHT=3D1 alt=3D" ">
<!-- Do NOT delete previous line if you want to get statistics on the numb=
er of opened emails -->
<center>
<!-- Begin Logo Include -->
<!-- START CONDITIONAL HTML HIDING=20
=20
<img src=3D"" border=3D"0" vspace=3D"2" alt=3D"Please contact u=
s for distributing your news to this mailing list!">
=20
END OF CONDITIONAL HTML HIDING -->=20
=20
<!-- End Logo Include -->
<table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" width=3D"575">
<tr>
=09<td width=3D"25"><img src=3D"http://ccprod.roving.com/roving/images/lett=
ers/gray-corner-tl.gif" width=3D"25" height=3D"25" border=3D"0" alt=3D""></=
td>
=09<td width=3D"525" bgcolor=3D"#666666">=A0</td>
=09<td width=3D"25" bgcolor=3D"#666666">=A0</td>
</tr>
<!-- Begin Title Row -->
<tr>
=09<td width=3D"25" bgcolor=3D"#666666">=A0</td>
=09<td width=3D"525" bgcolor=3D"#CCCCCC">=A0<font face=3D"Verdana,Geneva,Ar=
ial,Helvetica,sans-serif" size=3D"5" color=3D"#870000">BIOTAQ(TM) Newswire<=
/font></td>
=09<td width=3D"25" bgcolor=3D"#666666">=A0</td>
</tr>
<!-- End Title Row -->
<!-- Begin Date String Row -->
<tr>
=09<td width=3D"25" bgcolor=3D"#666666">=A0</td>
=09<td width=3D"525" bgcolor=3D"#CCCCCC" align=3D"right"><font face=3D"Verd=
ana,Geneva,Arial,Helvetica,sans-serif" size=3D"2" color=3D"#000000">July 3 =
2002</font>=A0</td>
=09<td width=3D"25" bgcolor=3D"#666666">=A0</td>
</tr>
<!-- End Date String Row -->
<tr>
=09<td width=3D"575" colspan=3D"3" height=3D"1" bgcolor=3D"#666666"><img sr=
c=3D"http://ccprod.roving.com/roving/images/letters/spacer.gif" width=3D"1"=
height=3D"1" border=3D"0" alt=3D""></td>
</tr>
<tr>
=09<td width=3D"25" bgcolor=3D"#870000">=A0</td>
=09<td width=3D"525" bgcolor=3D"#FFFFFF">
=09<!-- Begin Content Table -->
=09<table border=3D"0" cellpadding=3D"6" cellspacing=3D"0" width=3D"100%">
=09<tr>
=09=09<td width=3D"100%">
=09=09<font face=3D"Verdana,Geneva,Arial,Helvetica,sans-serif" size=3D"2" c=
olor=3D"#000000">
=09=09<!-- Begin Greeting -->
=09=09
=09=09<!-- End Greeting -->
=09=09
=09=09<!-- Begin Letter Body -->
<h3>
<font face=3D"Arial,Helvetica">AlphaRX Announces Commercialization of LipoB=
loc*
and LipoLette*, Two Unique Proprietary Dietary Supplements for the Manageme=
nt
of High Blood Cholesterol & Weight Control</font></h3>
Richmond Hill, Ontario - July 03, 2002 - AlphaRx Inc. (ALRX:OTCBB) is pleas=
ed
to announce that production has commenced of LipoBloc* and LipoLette* -
two of its proprietary dietary formulations addressing the multi-billion
dollar markets for the management of high blood cholesterol levels and
the promotion of sustainable long-term bodily weight-control. The
Company has begun manufacturing in preparation for their product launch,
anticipated for September 2002.
<p>Cardiovascular disease is the number one killer in the Western World,
with an estimated $200 billion spent on the disease annually. AlphaRx's
highly soluble LipoBloc* has been proven effective in the management of
high blood cholesterol levels, as there is a direct correlation between
the solubility of phytosterols and their effectiveness in cholesterol reduc=
tion.
AlphaRx's LipoBloc* offers consumers a viable dietary supplement that works
to reduce cholesterol levels.
<p>AlphaRx's clinically proven delivery system makes LipoBloc* significantl=
y
more soluble and bioavailable than other phytosterol products, enhancing
their attachment to cholesterol absorption sites in the small intestine
and further reducing serum total and LDL levels as a result. Phytoste=
rols
are naturally occurring plant extracts, which have a molecular structure
virtually identical to that of cholesterol but are insoluble in water and
oil, thus making them extremely low in bioavailability.
<p>In one clinical trial, 300 mg phytosterols administered in lecithin
micelles (such as those used in LipoBloc* reduced cholesterol absorption
as much as 34.4% as compared to a 11.5% reduction in three times the quanti=
ty
of phytosterols in powder form alone. Thus, there is clearly a direct corre=
lation
between the solubility of phytosterols and their effectiveness in cholester=
ol
absorption.
<p>It is estimated that consumers spend approximately $33 billion annually
trying to lose weight or prevent weight gain. AlphaRx's LipoLette*
supports effective weight control "lipotrophically" by decreasing the accum=
ulation
of fat in the body. LipoLette's* active ingredients include a natural
plant extract that though to inhibit the action of "lipases," intestinal
tract digestive enzymes that are responsible for the body's absorption
of fat. This inhibition achieves weight control through reduced fat
intake, eliminating the unabsorbed food through the stool. This mecha=
nism
is similar to the popular obesity drug "Xenical," a synthetic prescription
"lipase" inhibitor. As LipoLette* is also free of Ephedra (Ma Huang)
and caffeine, LipoLette* addresses the problem of weight control without
such adverse side effects as insomnia and agitation.
<p><b>About AlphaRx</b>
<br>AlphaRx is engaged in the development of novel formulations of drugs
that are insoluble or poorly soluble in water. AlphaRx's broad product
pipeline consists of carefully selected, currently marketed drugs, which,
through the application of its proprietary drug delivery technology, offer
improved medical benefits over existing products with a strong commercial
potential.
<p><b>FORWARD LOOKING STATEMENTS:</b>
<br>This release contains forward-looking statements within the meaning
and pursuant to the Safe Harbor provisions of the Securities Litigation
Reform Act of 1995 and involve risks and uncertainties that may individuall=
y
or mutually impact the matters herein described, including but not limited
to product development and acceptance, manufacturing, competition, regulato=
ry
and/or other factors, which are outside the control of the Company.
<p><b>Note</b>: The FDA has not evaluated these statements.
This statement is not intended to diagnose, treat, cure of prevent disease.
<p><b>Contact:</b>
<br>AlphaRx <a href=3D"http://www.alpharx.com">http://www.alpha=
rx.com</a>
Michael M. Lee Tel: 905-762-0745 Ext. 101
<p><b>Econ Investor Relations</b>
<br>Connie Linder
<br>Toll free: 888-368-8705
<br>Email: <a href=3D"mailto:clinder@investorideas.com">clinder@investoride=
as.com</a>
<br>
=09=09<p>
=09=09<p>
<p>
=09=09<p>
=09=09<p>
<p>
<p>
<p>
<p>
<p>
<p>
<p>
=09=09<p>
=09=09<!-- End Letter Body -->
=09=09
=09=09<!-- Begin Signature -->
=09=09<p>
=09=09
=09=09<p>Biotaq.com Support : You are invited to join Biotaq.com at http://=
www.biotaq.com/joinbiotaq.htm
=09=09<br>Please contact us for distributing your news to this mailing list=
!
=09=09<hr width=3D"60%" size=3D"1" align=3D"left" NOSHADE>
=09=09support@biotaq.com<br>
=09=09<a href=3D"http://rs6.net/tn.jsp?t=3Dg8sy4rn6.ad7u4rn6.vbwizqn6&p=3Dh=
ttp%3A%2F%2Fwww.biotaq.com">http://www.biotaq.com</a><br>
=09=09<!-- End Signature -->
=09=09</font>
=09=09</td>
=09</tr>
=09</table>
=09<!-- End Content Table -->
=09</td>
=09<td width=3D"25" bgcolor=3D"#870000">=A0</td>
</tr>
<!-- Begin Phone Number Row -->
<tr>
=09<td width=3D"25" bgcolor=3D"#870000">=A0</td>
=09<td width=3D"525" bgcolor=3D"#870000" align=3D"right"><font face=3D"Verd=
ana,Geneva,Arial,Helvetica,sans-serif" size=3D"1" color=3D"#FFFFFF">call us=
:: Michael M. Lee at 905-762-0745 Ext. 101</font></td>
=09<td width=3D"25"><img src=3D"http://ccprod.roving.com/roving/images/lett=
ers/red-corner-br.gif" width=3D"25" height=3D"25" border=3D"0" alt=3D""></t=
d>
</tr>
<!-- End Phone Number Row -->
<tr>
=09<td colspan=3D"3" bgcolor=3D"#FFFFFF" align=3D"center">
=09<!-- You are required by your Constant Contact user agreement to
provide the opt-out link shown below as by the property 'OptOut' -->
=09<font face=3D"Verdana,Arial,Helvetica,sans-serif" size=3D"1">
=09<br>This email was sent to by <a href=3D"http://rs6.net/tn.jsp?t=3Dg8s=
y4rn6.ad7u4rn6.vbwizqn6&p=3Dhttp%3A%2F%2Fwww.biotaq.com">Biotaq.com</a>. =
=20
=09<br>Visit our Subscription Center to <a href=3D"http://ccprod.roving.com=
/roving/d.jsp?p=3Doo&m=3D992813485921&ea=3Ddas@biodas.org">edit</a> your in=
terests or <a href=3D"http://ccprod.roving.com/roving/d.jsp?p=3Doo&m=3D9928=
13485921&ea=3Ddas@biodas.org">unsubscribe</a>.
=09<br>View our <a href=3D"http://ccprod.roving.com/roving/CCPrivacyPolicy.=
jsp">privacy policy</a>.
=09=09<!-- end opt-out area -->
=09</td>
</tr>
</table>
</center>
</body>
</html>
------=_Part_385011_-1966590049.1025681402550--